LSUHSC Minority Based Community Clinical Oncology

路易斯安那州立大学健康科学中心少数民族社区临床肿瘤学项目(LSUHSC MBCCOP)仍然是东南部少数民族人口获得和参与临床试验的极好工具 路易斯安那州。路易斯安那州几种常见恶性肿瘤的发病率在统计上显著增加 美国其余地区(监测、流行病学和最终结果[SEER]估计)。重要的是 大约70%的患者在国家医疗系统最大的城市医院(国家医疗中心 路易斯安那州新奥尔良分校[MCLNO])是非裔美国人。不幸的是，非洲裔美国人传统上一直 在获得和参与肿瘤学临床试验方面代表性不足。这种试验的作用是提供切割 为当地社区提供边缘治疗和预防策略。此外，少数民族在临床上的子集评估 试验还可能提供关于潜在的药物基因组差异的临床结果的重要信息。 非裔美国人对阵白人。然而，LSUHSC MBCCOP试图缩小参与试验的差距 在非裔美国人和高加索人之间。重要的是，MBCCOP为社区提供的临床试验 包括治疗和预防目标。LSUHSC MBCCOP的目标包括1)增加 通过针对多层次患者的干预措施，少数人获得和参与治疗性临床试验 关心。2)通过有针对性的干预措施，增加少数群体获得和参与癌症预防临床试验的机会 多层次的患者护理。3)评估患者获得和参与临床试验的障碍， 城市、学院式的医院系统。总而言之，LSUHSC MBCCOP寻求增加 少数民族人群通过教育和投资者发起了对这些障碍的评估。

The Louisiana State University Health Sciences Center Minority Based Community Clinical Oncology Program (LSUHSC MBCCOP) remains an excellent vehicle for clinical trials access and participation in the minority population of Southeast Louisiana. Louisiana has a statistically significantly increased incidence of several common malignancies over the remainder of the United States (Surveillance, Epidemiology and End Results [SEER] estimate). Importantly, approximately 70% of patients seen in the largest urban hospital of the state medical system (The Medical Center of Louisiana at New Orleans [MCLNO]) are African American. Unfortunately, African Americans have traditionally remained underrepresented in terms of access to and participation in oncology clinical trials. Such trials serve to provide cutting edge therapies and prevention strategies to the local community. Additionally, subset evaluations of minorities on clinical trials may also provide important information on the clinical outcomes of potential pharmacogenomic differences in African Americans versus Caucasians. However, the LSUHSC MBCCOP seeks to decrease the gap in trials participation between African Americans and Caucasians. Importantly, the clinical trials that the MBCCOP provides for the community encompass both therapeutic and prevention objectives. The aims of the LSUHSC MBCCOP include 1) To increase minority access to and participation in therapeutic clinical trials through interventions targeting multiple levels of patient care. 2) To increase minority access to and participation in cancer prevention clinical trials through interventions targeting multiple levels of patient care. 3) To evaluate barriers to access and participation in clinical trials by patients in a large, urban, academic hospital system. In summary, the LSUHSC MBCCOP seeks to increase trials participation of the minority population through education and investi_lator initiated evaluation of barriers to these _loals.